Metabolic dysfunction-associated steatohepatitis resulted in mean annualized all-cause healthcare costs exceeding $19,000 across all patient cohorts, ranging from $19,018 in those without metabolic comorbidities to $32,592 in those with metabolic syndrome.
Cohort (n=98,199)
Yes
All-cause healthcare costs for MASH patients remain high (>$19,000 annually) even in the absence of metabolic syndrome, elevated BMI, or type 2 diabetes.
Abstract Background Metabolic dysfunction-associated steatohepatitis (MASH) is commonly comorbid with metabolic syndrome; however, MASH can occur in the absence of metabolic syndrome. This retrospective cohort study evaluated the patient characteristics, healthcare utilization, and healthcare costs among patients with MASH with and without metabolic syndrome, obesity, and type 2 diabetes/elevated fasting glucose. Methods In a linked dataset of electronic health records (Veradigm Network EHR) and claims (Komodo Health), we identified adults with a MASH diagnosis code (7/1/2018-3/15/2023) and ≥12 months of continuous enrollment pre- and post-MASH diagnosis. Patients with other causes of liver disease, gestational or type 1 diabetes, or bariatric surgery were excluded. Six cohorts were identified: 1) MASH with metabolic syndrome, 2) MASH without metabolic syndrome, 3) MASH with body mass index (BMI) <25, 4) MASH with a BMI <25 and metabolic syndrome, 5) MASH with a BMI <25 without metabolic syndrome, and 6) MASH with a BMI <25 without metabolic syndrome or type 2 diabetes/elevated fasting glucose. We captured demographics, clinical characteristics, all-cause healthcare utilization, and costs. Results We identified 98, 199 patients with MASH, of which 34. 4% did not have metabolic syndrome, and 3. 1% had a BMI <25. Mean (standard deviation) annualized all-cause healthcare costs exceeded 19, 000 in all cohorts and ranged from 19, 018 (60, 359) among patients with a BMI <25 without metabolic syndrome or type 2 diabetes/elevated fasting glucose to 32, 592 (337, 462) among patients with metabolic syndrome. Median (interquartile range) costs ranged from 5, 336 (2, 085-14, 839) to 11, 373 (4, 478-27, 243), and mean costs after excluding the top 1% of spenders ranged from 14, 355 (25, 868) to 21, 878 (30, 755). Trends were consistent when the analysis was expanded to include patients without a documented BMI. Conclusions Metabolic syndrome is commonly comorbid with MASH; however, all-cause healthcare costs remain high even among the subpopulation without metabolic syndrome, elevated BMI, or type 2 diabetes/elevated fasting glucose.
Tapper et al. (Mon,) conducted a cohort in Metabolic dysfunction-associated steatohepatitis (MASH) (n=98,199). None (Observational study) vs. MASH without metabolic syndrome was evaluated on Annualized all-cause healthcare costs. Metabolic dysfunction-associated steatohepatitis resulted in mean annualized all-cause healthcare costs exceeding $19,000 across all patient cohorts, ranging from $19,018 in those without metabolic comorbidities to $32,592 in those with metabolic syndrome.